Clinical characteristics and outcomes of Chinese patients with KRAS‐mutant non‐small cell lung cancer after chemotherapy

Código QR

Clinical characteristics and outcomes of Chinese patients with KRAS‐mutant non‐small cell lung cancer after chemotherapy

Guardado en:

Detalles Bibliográficos
Autores principales:	Yawen Zheng, Qinghua Lai, Hanxi Zhao, Xiaolin Li, Xiaorong Sun, Ligang Xing
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/51692c5502fc4d01b2a2f4b714f023fc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

SOD1 regulates ribosome biogenesis in KRAS mutant non-small cell lung cancer
por: Xiaowen Wang, et al.
Publicado: (2021)

Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer
por: Giorgia Maroni, et al.
Publicado: (2021)

Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer
por: Chia-I Shen, et al.
Publicado: (2021)

Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma
por: Sarah A. Best, et al.
Publicado: (2019)

Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer
por: Marzia Del Re, et al.
Publicado: (2017)

A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
por: Nicolas Bery, et al.
Publicado: (2020)

Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
por: Jieqiong Wang, et al.
Publicado: (2016)

Retrospective analysis of outcomes and prognostic factors of chemotherapy for small-cell lung cancer
por: Minami S, et al.
Publicado: (2016)

Mutant KRAS promotes malignant pleural effusion formation
por: Theodora Agalioti, et al.
Publicado: (2017)

Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes
por: Gabriela Palma, et al.
Publicado: (2021)

Targeting the DNA replication stress phenotype of KRAS mutant cancer cells
por: Tara Al Zubaidi, et al.
Publicado: (2021)

Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients
por: Madiha Naseem, et al.
Publicado: (2021)

Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting
por: Adham S. Bear, et al.
Publicado: (2021)

PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.
por: Lei Wang, et al.
Publicado: (2014)

Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers
por: David H. Peng, et al.
Publicado: (2021)

Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers
por: Soonsil Hyun, et al.
Publicado: (2021)

KRAS regulation by small non-coding RNAs and SNARE proteins
por: Yonglu Che, et al.
Publicado: (2019)

Personalized medicine of non-gene-specific chemotherapies for non-small cell lung cancer
por: Wenxiao Jiang, et al.
Publicado: (2021)

Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade
por: Guido Kroemer, et al.
Publicado: (2021)

Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study
por: Jean-Louis Pujol, MD, PhD, et al.
Publicado: (2021)

Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer
por: Jiawen Yang, et al.
Publicado: (2021)

Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases
por: Adam Lauko, et al.
Publicado: (2021)

Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes
por: Si-Yang Liu, et al.
Publicado: (2021)

Targeting MERTK and AXL in <i>EGFR</i> Mutant Non-Small Cell Lung Cancer
por: Dan Yan, et al.
Publicado: (2021)

Small-cell lung cancer growth inhibition: synergism between NMDA receptor blockade and chemotherapy
por: North WG, et al.
Publicado: (2019)

m6A regulators as predictive biomarkers for chemotherapy benefit and potential therapeutic targets for overcoming chemotherapy resistance in small-cell lung cancer
por: Zhihui Zhang, et al.
Publicado: (2021)

Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status
por: Hong Jian, et al.
Publicado: (2017)

Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma
por: Huai-Qiang Ju, et al.
Publicado: (2017)

Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis
por: Li-Ming Tan, et al.
Publicado: (2017)

Characteristics and adverse outcomes of Chinese adolescent pregnancies between 2012 and 2019
por: Yanxia Xie, et al.
Publicado: (2021)

The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer
por: Jessica A. Moerland, et al.
Publicado: (2020)

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
por: Nathaniel Wiest, et al.
Publicado: (2021)

The Ki-67 Proliferation Index-Related Nomogram to Predict the Response of First-Line Tyrosine Kinase Inhibitors or Chemotherapy in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor-Mutant Status
por: Weiguo Gu, et al.
Publicado: (2021)

The influence of genetic polymorphisms on the toxicity of platinum-based chemotherapy in the treatment of non-small cell lung cancer
por: Spasić Jelena, et al.
Publicado: (2021)

Combination chemotherapy of gemcitabine and vinorelbine for pretreated non-small- cell lung cancer: a retrospective study
por: Minami S, et al.
Publicado: (2015)

The use of atezolizumab in combination with chemotherapy in first-line of metastatic small cell lung cancer. Case report
por: Nikolai A. Ognerubov, et al.
Publicado: (2021)

p.G12C KRAS mutation prevalence in non-small cell lung cancer: Contribution from interregional variability and population substructures among Hispanics
por: Alejandro Ruiz-Patiño, et al.
Publicado: (2022)

The Clinical Characteristics and Outcomes of Follicular Bronchiolitis in Chinese Adult Patients
por: Ju Lu, et al.
Publicado: (2018)

NOS2-deficient mice with hypoxic necrotizing lung lesions predict outcomes of tuberculosis chemotherapy in humans
por: Martin Gengenbacher, et al.
Publicado: (2017)

The integrated stress response is tumorigenic and constitutes a therapeutic liability in KRAS-driven lung cancer
por: Nour Ghaddar, et al.
Publicado: (2021)